{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055815","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.251635+00:00","generated_at":"2026-06-15T20:51:27.076369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cellectar reports Q1 net loss of $8.6M; cash at $12.7M with runway into Q4 2023","bullets":["Net loss of ($8.6M) or ($0.76)/share vs ($6.1M) or ($1.00)/share in Q1 2022.","Cash and equivalents $12.7M at March 31, 2023, down from $19.9M at Dec 31, 2022.","R&D expense rose to $6.7M from $3.9M YoY on clinical, manufacturing costs.","G&A expense decreased to $2.1M from $2.3M YoY driven by lower professional fees.","Enrolling pivotal iopofosine trial in Waldenstrom's; topline data expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055815","json":"https://secwatch.observer/filing/0001104659-23-055815.json","markdown":"https://secwatch.observer/filing/0001104659-23-055815.md","text":"https://secwatch.observer/filing/0001104659-23-055815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/0001104659-23-055815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/tm2314664d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:51:27.076369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01286097cdae28ba0b5a398501f59c80b1200454","claim":"Cellectar Biosciences, Inc. reported three months ended March 31, 2023 results: net income ($8.6) million, EPS ($0.76) per share.","evidence_excerpt":"The net loss attributable to common stockholders for the three months ended March 31, 2023 was ($8.6) million, or ($0.76) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/0001104659-23-055815-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"($8.6) million"},{"label":"EPS","value":"($0.76) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}